Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Journal of Gastroenterology
Published in: Clinical Journal of Gastroenterology 5/2020

01-10-2020 | Vulgar Psoriasis | Case Report

Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma

Authors: Tomoko Adachi, Atsushi Hiraoka, Hidenori Okazaki, Kensuke Nagamatsu, Hirofumi Izumoto, Takeaki Yoshino, Miho Tsuruta, Toshihiko Aibiki, Tomonari Okudaira, Hiroka Yamago, Ryuichiro Iwasaki, Yoshifumi Suga, Kenichiro Mori, Hideki Miyata, Eiji Tsubouchi, Tomoyuki Ninomiya, Kojiro Michitaka

Published in: Clinical Journal of Gastroenterology | Issue 5/2020

Login to get access

Abstract

We treated a 66-year-old Japanese male with unresectable hepatocellular carcinoma (u-HCC) for multiple (>5) liver tumors (maximum 2.6 cm in size, Child–Pugh B score 7) in September 2018. The patient had a history of psoriasis vulgaris and sorafenib (SOR) was introduced (800 mg/day) because of transcatheter arterial chemoembolization (TACE) refractoriness. However, psoriasis vulgaris exacerbation and a high fever were observed 2 weeks later, and the patient was admitted, after which improvement of psoriasis vulgaris was obtained with external medicine administration and SOR intake discontinuation. Few reports have noted exacerbation of psoriasis vulgaris caused by SOR treatment.
Literature
1.
Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.CrossRef
2.
Kudo M, Matsui O, Izumi N, et al. Transarterial chemoembolization failure/refractoriness: JSH–LCSGJ criteria 2014 update. Oncology. 2014;87(Suppl 1):22–31.CrossRef
3.
Ogasawara S, Chiba T, Ooka Y, et al. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014;87:330–41.CrossRef
4.
Arizumi T, Ueshima K, Minami T, et al. Effectiveness of sorafenib in patients with transcatheter arterial chemoembolization (TACE) refractory and intermediate-stage hepatocellular carcinoma. Liver Cancer. 2015;4:253–62.CrossRef
5.
Ogawa C, Morita M, Omura A, et al. Hand–foot syndrome and post-progression treatment are the good predictors of better survival in advanced hepatocellular carcinoma treated with sorafenib: a multicenter study. Oncology. 2017;93(Suppl 1):113–9.CrossRef
6.
Kudo M, Matsui O, Izumi N, et al. JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer. 2014;3:458–68.CrossRef
7.
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163–73.CrossRef
8.
Hiraoka A, Kumada T, Kariyama K, et al. Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis. Hepatol Res. 2019;49:111–7.
9.
Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56–66.CrossRef
10.
Zhu AX, Finn RS, Galle PR, et al. Ramucirumab in advanced hepatocellular carcinoma in REACH-2: the true value of alpha-fetoprotein. Lancet Oncol. 2019;20:e191.CrossRef
11.
Hiraoka A, Kumada T, Kudo M, et al. Hepatic function during repeated tace procedures and prognosis after introducing sorafenib in patients with unresectable hepatocellular carcinoma: multicenter analysis. Dig Dis. 2017;35:602–10.CrossRef
12.
Peck-Radosavljevic M, Kudo M, Raoul J, et al. Outcomes of patients (pts) with hepatocellular carcinoma (HCC) treated with transarterial chemoembolization (TACE): global OPTIMIS final analysis. J Clin Oncol. 2018;36:4018.CrossRef
13.
Yan BX, Zheng YX, Li W, et al. Comparative expression of PEDF and VEGF in human epidermal keratinocytes and dermal fibroblasts: from normal skin to psoriasis. Discov Med. 2018;25:47–56.
14.
Crawshaw AA, Griffiths CE, Young HS. Investigational VEGF antagonists for psoriasis. Expert Opin Investig Drugs. 2012;21:33–43.CrossRef
15.
Antoniou EA, Koutsounas I, Damaskos C, et al. Remission of psoriasis in a patient with hepatocellular carcinoma treated with sorafenib. Vivo. 2016;30:677–80.
16.
van Kester MS, Luelmo SAC, Vermeer MH, et al. Remission of psoriasis during treatment with sorafenib. JAAD Case Rep. 2018;4:1065–7.CrossRef
17.
Datta-Mitra A, Riar NK, Raychaudhuri SP. Remission of psoriasis and psoriatic arthritis during bevacizumab therapy for renal cell cancer. Indian J Dermatol. 2014;59:632.CrossRef
18.
Diamantis ML, Chon SY. Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. J Drugs Dermatol. 2010;9:169–71.
19.
Gonzalez-Lopez MA, Gonzalez-Vela MC, Yanez S, et al. Psoriasiform skin eruption associated with sorafenib therapy. Indian J Dermatol Venereol Leprol. 2011;77:614–5.CrossRef
20.
Hung CT, Chiang CP, Wu BY. Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy. J Dermatol. 2012;39:1076–7.CrossRef
21.
Laquer V, Saedi N, Dann F, et al. Sorafenib-associated psoriasiform skin changes. Cutis. 2010;85:301–2.
22.
Ilknur T, Akarsu S, Carsanbali S, et al. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma. J Drugs Dermatol. 2014;13:899–900.
23.
Hsu M, Chen C. Psoriasis flare-ups following sorafenib therapy: a rare case. Dermatologica Sinica. 2016;34:148–50.CrossRef
24.
Bourne EL, Day T, Scurry J. Regorafenib-associated vulvar psoriasiform skin reaction: case of the month from the ISSVD case consultation committee. J Low Genit Tract Dis. 2016;20:e44–45.CrossRef
Metadata
Title
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma
Authors
Tomoko Adachi
Atsushi Hiraoka
Hidenori Okazaki
Kensuke Nagamatsu
Hirofumi Izumoto
Takeaki Yoshino
Miho Tsuruta
Toshihiko Aibiki
Tomonari Okudaira
Hiroka Yamago
Ryuichiro Iwasaki
Yoshifumi Suga
Kenichiro Mori
Hideki Miyata
Eiji Tsubouchi
Tomoyuki Ninomiya
Kojiro Michitaka
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Clinical Journal of Gastroenterology / Issue 5/2020
Print ISSN: 1865-7257
Electronic ISSN: 1865-7265
DOI
https://doi.org/10.1007/s12328-020-01134-3

Other articles of this Issue 5/2020

Clinical Journal of Gastroenterology 5/2020 Go to the issue

Case Report

A case of an enlarged rectal adenoma while achieving a clinical complete response with chemotherapy for advanced rectal cancer

Clinical Review

Towards screening Barrett’s oesophagus: current guidelines, imaging modalities and future developments

Case Report

Late recurrence of gastric carcinoma 15 years after surgery

Case Report

The rare case of elevated signet ring cell gastric carcinoma with Helicobacter pylori-naïve mucosa

Case Report

Eosinophilic esophagitis with a severe stenosis: report of a Japanese case

Case Report

Portal vein aneurysm with complete spontaneous regression after 10 years using conservative treatment
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits